Document text
Principal Investigator: Lisa A Cavacini
Organization: UNIV OF MASSACHUSETTS MED SCH WORCESTER
Fiscal Year: 2022
Award: $694,299
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
The coronavirus disease 2019 (COVID-19) rapidly disseminated through the human population
and became a global pandemic. Significant efforts have been put into developing vaccines or
antibody therapies based on the spike glycoprotein of SARS-CoV-2. One challenge of such
strategies is to identify conserved epitopes on the Spike and predict viral mutations that could
diminish the effectiveness of the vaccine and immunotherapy. To date, over 20 variant of SARS-
CoV-2 genome sequences have been reported. Therefore, structure guided and epitope based
design are crucial to generate effective medicines for current and future outbreaks of SARS-CoV-
2 or related coronavirus. Nanobodies can recognize conserved epitopes on hypervariable
pathogens. Here, we propose that anti-spike nanobodies can be utilized for rapid identification of
protective epitopes to inform design of vaccine and therapeutics. Further, we hypothesize that
potent and broadly protective nanobodies against SARS-CoV-2 can be developed as an inhaled
prophylactic or therapeutic medicine.
In this proposal, we will leverage our complementary strengths through a multi-disciplinary
approach combining mucosal immunology, structural biology, and virology, to characterize the
molecular interactions and differential specificities of a diverse panel of nanobodies against spike
of SARS-CoV-2 and other members of the Betacoronaviruese family (Aim 1). A comprehensive
list of conserved and non-conserved epitopes (Aim 2) will be used for structure-based design of
potent nanobody multimers for in vivo characterization (Aim 3).
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Address><Affinity><Airway mucosa><Animal Model><Animal Models and Related Studies><Animals><Antibody Therapy><Antigenic Determinants><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Binding><Binding Determinants><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><COVID-19><COVID-19 S protein><COVID-19 genome><COVID-19 infection><COVID-19 outbreak><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus genome><COVID19><COVID19 S protein><COVID19 genome><COVID19 infection><COVID19 outbreak><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><COVID19 virus genome><CV-19><CV19><Characteristics><CoV-2><CoV2><Communicable Diseases><Complement><Complement Proteins><Complex><Coronaviridae><Coronavirus><Crystallization><Development and Research><Disease Outbreaks><ELISA><Emerging Communicable Diseases><Emerging Infectious Diseases><Engineering><Enzyme-Linked Immunosorbent Assay><Epitope Mapping><Epitopes><Family><Fc domain><Future><Generations><Genetic Alteration><Genetic Change><Genetic defect><Glycoproteins><High Throughput Assay><Human><IgA><Immune mediated therapy><Immunity><Immunoglobulin A><Immunologically Directed Therapy><Immunology><Immunotherapy><In Vitro><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inhalation><Inhaling><Knowledge><Massachusetts><Medicine><Modern Man><Molecular Interaction><Morbidity><Morbidity - disease rate><Mucosa><Mucosal Tissue><Mucous Membrane><Mutation><NIAID><Nasal><Nasal Passages Nose><National Institute of Allergy and Infectious Disease><Nose><Outbreaks><Population><Position><Positioning Attribute><Preventative intervention><Proteins><R & D><R&D><Receptor Protein><Reporting><Respiratory Mucosa><Respiratory System, Nose, Nasal Passages><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 genome><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 genome><SARS-CoV2 infection><SARS-CoV2 outbreak><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Site><Solubility><Specificity><Structural Biologist><Structure><Testing><Therapeutic><Therapeutic antibodies><Translating><Universities><VAC-TX><Vaccine Design><Vaccine Therapy><Variant><Variation><Viral><Virus><Wuhan coronavirus><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antiviral compound><antiviral medication><antiviral therapeutic><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><biologics><biopharmaceutical><biotherapeutic agent><corona virus><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 genome><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus genome><coronavirus disease-19><coronavirus disease-19 outbreak><coronavirus disease-19 virus><coronavirus infectious disease-19><design><designing><develop a vaccine><develop therapy><develop vaccines><development of a vaccine><enzyme linked immunoassay><experience><genome mutation><global health><hCoV19><high throughput screening><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><in vitro activity><in vitro testing><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><interdisciplinary approach><intermolecular interaction><intervention design><intervention development><intervention for prevention><medical college><medical schools><member><model of animal><model organism><mortality><multidisciplinary approach><nCoV2><nanobodies><nanobody><neutralizing antibody><novel><pandemic><pandemic disease><pathogen><prevention intervention><preventional intervention strategy><preventive intervention><prophylactic><receptor><receptor binding><receptor bound><research and development><school of medicine><sdAb><severe acute respiratory syndrome coronavirus 2 genome><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><single domain antibodies><social><structural biology><therapeutic vaccination><therapy design><therapy development><thermolability><thermostability><treatment design><treatment development><vaccine development><vaccine effectiveness><vaccine efficacy><virology><β CoV><β coronavirus><βCoV>